Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?

GLP-1s are more than just weight loss drugs. They're a chance to rewrite our evolutionary story, to take control of our biology in a way never before possible.

Healthcare Vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?With public understanding divided on the causes of obesity, this paper aims to transcend the debate between personal responsibility and disease status to offer a fresh perspective – that obesity is an evolutionary trap. Specifically, it examines:

  • Why human biology creates an inherent vulnerability to obesity
  • How amplifying our natural GLP-1 levels can address multiple different diseases
  • The current status of GLP-1 drug approvals by condition
  • The unprecedented questions we now face about equity, access & our collective future

Read our thought-provoking analysis today

Related news

  • Automotive Disruption and Trends Webinar
    Consumers Webinar

    Automotive Disruption and Trends Webinar

    Please join Ipsos and SAA for a discussion on the future of mobility based on insights from the 2025 Ipsos Navigator Study.
  • Obesity Week
    Public Health Event

    Obesity Week

    This is a conference that encompasses the full spectrum of obesity science: from basic science research, to translational research and clinical application, to public policy; from diet, exercise, lifestyle, and psychology to medical and surgical interventions; from pediatric to geriatric to underserved populations.
  • EPHMRA: Human Factors for Devices & Drugs
    Public Health Webinar

    EPHMRA: Human Factors for Devices & Drugs

    Ipsos is delighted to join EPHMRA for a 45-minute webinar discussion that will move beyond the basics to explore the application of HF research today.